Fundies.
English

Edgewise Therapeutics, Inc.

EDGAR
EWTX Quarterly report (10-Q) · filed 2026-08-06

25 filing records in this dataset, filed from 2021-03-05 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
72.3 million Unit_Standard_USD_1_GGO0xPIUeDgAZR8RNOyQ Source
Exact value

72319000 Unit_Standard_USD_1_GGO0xPIUeDgAZR8RNOyQ

Long-term debt including current maturities
59 thousand Unit_Standard_USD_jqmBvwKRJ0unUCi28AHYwg Source
Exact value

59000 Unit_Standard_USD_jqmBvwKRJ0unUCi28AHYwg

Shares outstanding
108 million Unit_Standard_shares_Awxp7yBxWUOYZQqkLT-76g Source
Exact value

107776380 Unit_Standard_shares_Awxp7yBxWUOYZQqkLT-76g

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 3 of 11 periods available· newest 2025-12-31
  • Net income: 3 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 3 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 3 of 11 periods available· newest 2025-12-31
  • Total assets: Multiple units; comparison withheld· newest 2025-12-31
  • Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Current assets: Multiple units; comparison withheld· newest 2025-12-31
  • Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 33.98 million

    Prior period

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 133.81 million

    –

    Current period

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 167.8 million

    –

    Exact inputs and evidence

    -167795000 − -133813000 = -33982000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

    -133813000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -167795000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 34.79 million

    Prior period

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 109.03 million

    –

    Current period

    −Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 143.82 million

    –

    Exact inputs and evidence

    -143816000 − -109028000 = -34788000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

    -109028000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -143816000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    -80.5%

    Prior period

    Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 1.31 million

    –

    Current period

    Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 256,000

    –

    Exact inputs and evidence

    256000 − 1312000 = -1056000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

    1312000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    256000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2023 2023-01-01 – 2023-12-31
−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 100.16 million
Exact value

Exact value: -100163000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2023-01-01 – 2023-12-31: -100163000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 91.95 million
Exact value

Exact value: -91948000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2023-01-01 – 2023-12-31: -91948000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 5.75 million
Exact value

Exact value: 5745000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2023-01-01 – 2023-12-31: 5745000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 97.69 million
Calculation and evidence

-91948000 − 5745000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Exact free cash flow: -97693000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2024 2024-01-01 – 2024-12-31
−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 133.81 million
Exact value

Exact value: -133813000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2024-01-01 – 2024-12-31: -133813000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 109.03 million
Exact value

Exact value: -109028000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2024-01-01 – 2024-12-31: -109028000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 1.31 million
Exact value

Exact value: 1312000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2024-01-01 – 2024-12-31: 1312000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 110.34 million
Calculation and evidence

-109028000 − 1312000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Exact free cash flow: -110340000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 167.8 million
Exact value

Exact value: -167795000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2025-01-01 – 2025-12-31: -167795000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 143.82 million
Exact value

Exact value: -143816000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2025-01-01 – 2025-12-31: -143816000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 256,000
Exact value

Exact value: 256000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

2025-01-01 – 2025-12-31: 256000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag 144.07 million
Calculation and evidence

-143816000 − 256000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Exact free cash flow: -144072000 Unit_Standard_USD_q3JqIVCX7UOYYfnRMx1eag

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

25 filings · 2,458 latest values · 2,458 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001710072, 1710072, EWTX, edgar:1710072

Also known as Edgewise Therapeutics, Inc., Edgewise Therapeutics, Inc.